[HTML][HTML] Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
B Cao, Y Wang, H Lu, C Huang, Y Yang… - … England Journal of …, 2024 - Mass Medical Soc
Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus …
L Tian, T Qiang, X Yang, Y Gao, X Zhai, K Kang… - European Journal of …, 2023 - Elsevier
Although no longer a public health emergency of international concern, COVID-19 remains
a persistent and critical health concern. The development of effective antiviral drugs could …
a persistent and critical health concern. The development of effective antiviral drugs could …
Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116)
Q Cao, Y Ding, Y Xu, M Li, R Zheng, Z Cao, W Wang… - Frontiers of …, 2024 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic agents that target severe acute respiratory syndrome …
efforts to develop therapeutic agents that target severe acute respiratory syndrome …
Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19
KW Zhu - ACS Pharmacology & Translational Science, 2023 - ACS Publications
Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged)
were approved by the Chinese National Medical Products Administration for the treatment of …
were approved by the Chinese National Medical Products Administration for the treatment of …
[HTML][HTML] Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2
Abstract The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has evoked a worldwide pandemic. As the …
syndrome coronavirus-2 (SARS-CoV-2) has evoked a worldwide pandemic. As the …
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
YQ Xiao, J Long, SS Zhang, YY Zhu, SX Gu - Bioorganic Chemistry, 2024 - Elsevier
The COVID-19 pandemic continues to pose a threat to global health, and sounds the alarm
for research & development of effective anti-coronavirus drugs, which are crucial for the …
for research & development of effective anti-coronavirus drugs, which are crucial for the …
3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and …
VMF Amorim, EP Soares, ASA Ferrari, DGS Merighi… - Viruses, 2024 - mdpi.com
Proteases represent common targets in combating infectious diseases, including COVID-19.
The 3-chymotrypsin-like protease (3CLpro) is a validated molecular target for COVID-19 …
The 3-chymotrypsin-like protease (3CLpro) is a validated molecular target for COVID-19 …
Adverse drug reactions associated with COVID-19 management
V Chavda, P Dodiya, V Apostolopoulos - … -Schmiedeberg's Archives of …, 2024 - Springer
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
outbreak, which causes COVID-19, had a devastating impact on both people's lives and the …
outbreak, which causes COVID-19, had a devastating impact on both people's lives and the …
On the origins of SARS-CoV-2 main protease inhibitors
YL Janin - RSC Medicinal Chemistry, 2024 - pubs.rsc.org
In order to address the world-wide health challenge caused by the COVID-19 pandemic, the
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-Mpro) coded by its nsp5 gene …
A validated LC-MS/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats
Z Xu, C Li, X Qian, H Duan, J Zhou, Q Zhang… - … of Chromatography B, 2024 - Elsevier
Antiviral treatment for COVID-19 is considered an effective tool in reducing the rate of severe
cases and deaths. As of June 2023, a total of six small molecule antiviral drugs have been …
cases and deaths. As of June 2023, a total of six small molecule antiviral drugs have been …